FibriCheck vs KardiaAI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

FibriCheck

by FibriCheck

KardiaAI

by AliveCor

AI Verdict

FibriCheck provides a complete, smartphone camera-based PPG solution for direct patient heart rhythm monitoring and arrhythmia detection, including a healthcare professional portal. KardiaAI, while also detecting various cardiac conditions through AI-powered analysis, operates as an ECG analysis library that can be integrated into other devices and software, and is offered to end-users via subscription services likely paired with AliveCor's ECG devices. They are adjacent competitors due to their shared goal of cardiac arrhythmia detection and patient monitoring, but differ in their core measurement technology (PPG vs. ECG) and primary deployment models.

Choose FibriCheck if…

Choose FibriCheck if you are a patient seeking a convenient, smartphone camera-based solution for regular heart rhythm monitoring and detection of arrhythmias like AFib, or if you are a healthcare provider looking to offer patients an accessible tool for self-monitoring that also allows for logging of other vital signs. This tool is ideal for on-demand checks using a device most people already own, with the option for professional review.

View FibriCheck →

Choose KardiaAI if…

Choose KardiaAI if you are a developer or a healthcare organization aiming to integrate a robust, FDA-cleared AI-powered ECG analysis engine into your existing medical devices, mobile applications, or telehealth platforms. This solution is best suited for enhancing the diagnostic capabilities of other ECG recording systems with advanced detection of a wide range of cardiac conditions, including specific ECG abnormalities beyond just AFib.

View KardiaAI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	FibriCheck	KardiaAI
Pricing	Subscription-based, with options for monthly or annual payments. prices vary by region and may be partly or fully covered by insurance or employer.	Subscription-based for advanced features and services.
Deployment	Cloud-based (private cloud).	Mobile app, cloud-based.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

FibriCheck

FibriCheck (Tool A) leverages the ubiquitous smartphone camera for heart rhythm measurement, offering direct patient-facing usability without requiring additional hardware. KardiaAI (Tool B) is an API library, meaning it integrates into other applications or devices, making it less of a direct end-user tool and more of a backend component.

Clinical Value

KardiaAI

Both tools are FDA-cleared and clinically validated for arrhythmia detection. However, KardiaAI (Tool B) explicitly lists a broader and more specific range of detectable conditions, including various ectopic beats (PVCs, Wide QRS, SVE), and is based on ECG analysis, which is generally considered the gold standard for detailed cardiac rhythm assessment.

Pricing & Value

FibriCheck

FibriCheck (Tool A) offers a lower entry-level monthly subscription for end-users (u20ac6.99 vs. $13.99 for KardiaAI). Additionally, FibriCheck provides flexible, short-term doctor-prescribed options and an optional expert review, offering more granular and potentially cost-effective choices for specific monitoring needs.

Enterprise Readiness

KardiaAI

While both are HIPAA compliant and FDA cleared, KardiaAI (Tool B) is deployed as an API library, explicitly designed for integration into other mobile apps and web platforms, which offers superior flexibility for enterprise adoption and embedding into existing healthcare workflows. Tool B also explicitly states it has a BAA, whereas Tool A only implies it.

Innovation

FibriCheck

FibriCheck (Tool A) demonstrates significant innovation by transforming a standard smartphone camera into a medical device for PPG-based heart rhythm monitoring, making cardiac screening highly accessible without specialized hardware. While KardiaAI's (Tool B) advanced ECG analysis algorithms are innovative, FibriCheck's approach to leveraging existing consumer technology for a medical purpose is arguably more disruptive in terms of broad accessibility.

Support & Docs

Tie

Both FibriCheck (Tool A) and KardiaAI (Tool B) appear to offer standard support resources, including help centers, FAQs, and contact options for their respective user bases. Without more specific details on the quality or breadth of these resources, it is difficult to definitively distinguish between the two.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	FibriCheck	KardiaAI
Product Name	FibriCheck	KardiaAI
Company	Qompium nv	AliveCor
Primary Measurement Technology	Smartphone camera-based PPG technology for heart rhythm measurement	AI-powered ECG analysis library for ambulatory ECG rhythms
Key Arrhythmia Detections	Atrial Fibrillation (AFib) and other arrhythmias	Atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE)
Healthcare Professional Integration	Healthcare professional portal/dashboard for patient monitoring; Customizable monitoring rules for healthcare providers.	API library for integration into other ECG devices and software.

Videos

Demos, reviews, and walkthroughs featuring FibriCheck and KardiaAI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do the underlying technologies (smartphone camera-based PPG for FibriCheck vs. AI-powered ECG analysis library for KardiaAI) influence their respective clinical utility for diagnosis, screening, and long-term monitoring?

FibriCheck leverages smartphone camera-based photoplethysmography (PPG) for heart rhythm measurement, making it suitable for patient-driven, continuous monitoring and screening for arrhythmias like AFib without additional hardware. KardiaAI, as an AI software library, analyzes ambulatory ECG rhythms, offering more specific diagnostic insights for conditions such as AFib, bradycardia, tachycardia, PVCs, SVE, and Wide QRS, and is designed to integrate into existing ECG devices and software. This means FibriCheck is ideal for broad, accessible screening and long-term patient monitoring, while KardiaAI enhances the diagnostic capabilities of existing ECG workflows.

What is the depth and flexibility of EHR integration offered by each tool, and how does data flow into a physician's existing patient records for review and documentation?

FibriCheck offers API-based integration into existing EHRs, RPM platforms, and population health systems, providing a healthcare professional portal for patient monitoring and clinical reports. KardiaAI provides EHR integration capabilities, allowing ECGs from patients to be automatically and seamlessly pulled into EHR systems, and partners with leading EHR software and cardiac information management systems like GE Healthcare's MUSEu2122 NX. Both aim to streamline data flow, with FibriCheck focusing on its portal and API, and KardiaAI on integrating its analysis into existing ECG and EHR infrastructures.

What are the reported accuracy, sensitivity, and specificity rates for each tool in detecting various arrhythmias, particularly AFib, and how do they compare across different patient populations?

FibriCheck has demonstrated high accuracy for AF detection, with reported sensitivity of 96.3% and specificity of 99.3% in multicenter validation studies, and an overall accuracy of 98.5% for AF detection. KardiaAI's algorithm for AF detection has shown a sensitivity of 98.9% and specificity of 95.3% in one study, and a pooled sensitivity of 94% and specificity of 96.8% for Kardia Mobile in another review. While both offer medical-grade accuracy, FibriCheck's data is based on PPG from smartphones, and KardiaAI's on ECG analysis.

What is the expected learning curve for both clinical staff and patients, and how much additional staff time is typically required for managing and interpreting data from each system?

FibriCheck is designed for ease of use, with patients using their own smartphone camera for 60-second measurements, and a provider portal for clinicians to review summarized rhythm strips and manage alerts. A study on FibriCheck indicated a steep learning curve for patients, with the frequency of insufficient quality measurements decreasing significantly over a week. For KardiaAI, the learning curve for end-users of integrated systems would depend on the specific implementation, but its AI-powered analysis aims to reduce manual interpretation time for clinicians.

For larger practices or health systems, what are the key considerations for a multi-site rollout, and how does each tool support scalability and centralized management of patient data?

FibriCheck is a cloud-based digital application designed for population-scale deployment, enabling scalability from hundreds to hundreds of thousands of members without device overhead, and integrates into existing care ecosystems. KardiaAI, as an API library, supports integration into various platforms, and AliveCor's enterprise platform allows third-party providers to manage patient heart conditions, implying scalability through integration into larger systems. Both offer solutions for managing patient data, with FibriCheck providing a centralized provider portal and KardiaAI enabling data import into enterprise systems.

Are there opportunities to review case studies or connect with existing physician users to understand real-world implementation and outcomes, and what level of ongoing technical and clinical support is provided?

FibriCheck has published case studies on its global scaling and implementation in health systems, and reports over 100 peer-reviewed publications validating its technology. KardiaAI (AliveCor) also provides case studies and clinical validation studies, and offers resources for physicians to learn more about its technology and implementation. Both companies emphasize clinical validation and offer support, with FibriCheck providing automated analysis with human oversight and KardiaAI offering technical support for SDK integration.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring FibriCheck or KardiaAI

Backers

Who funded each tool's parent company.